Cryoport, Inc. (NASDAQ:CYRX) Shares Sold by Legal & General Group Plc

Legal & General Group Plc trimmed its holdings in Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 90.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,900 shares of the company's stock after selling 47,667 shares during the quarter. Legal & General Group Plc's holdings in Cryoport were worth $38,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently bought and sold shares of CYRX. Geode Capital Management LLC increased its position in Cryoport by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,097,369 shares of the company's stock valued at $8,902,000 after buying an additional 38,520 shares in the last quarter. LPL Financial LLC increased its holdings in shares of Cryoport by 1,366.1% during the fourth quarter. LPL Financial LLC now owns 436,766 shares of the company's stock valued at $3,398,000 after acquiring an additional 406,976 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Cryoport by 0.4% in the 4th quarter. Franklin Resources Inc. now owns 387,131 shares of the company's stock worth $3,012,000 after purchasing an additional 1,512 shares during the last quarter. Norges Bank bought a new position in Cryoport in the 4th quarter worth about $2,711,000. Finally, JPMorgan Chase & Co. increased its stake in Cryoport by 10.8% during the 4th quarter. JPMorgan Chase & Co. now owns 338,315 shares of the company's stock valued at $2,632,000 after purchasing an additional 33,078 shares in the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Cryoport

In related news, CEO Jerrell Shelton sold 4,620 shares of Cryoport stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the sale, the chief executive officer now directly owns 765,399 shares in the company, valued at $4,814,359.71. The trade was a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders sold 19,830 shares of company stock worth $118,353 in the last 90 days. 10.10% of the stock is owned by corporate insiders.

Cryoport Price Performance

NASDAQ:CYRX traded up $0.40 during trading hours on Friday, hitting $5.86. 345,885 shares of the stock traded hands, compared to its average volume of 546,000. The stock has a 50 day moving average price of $5.80 and a 200 day moving average price of $6.90. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. Cryoport, Inc. has a 1 year low of $4.58 and a 1 year high of $16.89. The company has a market cap of $293.80 million, a price-to-earnings ratio of -1.73 and a beta of 1.92.

Cryoport (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The business had revenue of $59.53 million during the quarter, compared to the consensus estimate of $58.71 million. During the same quarter in the prior year, the firm posted ($0.29) EPS. Sell-side analysts forecast that Cryoport, Inc. will post -0.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on CYRX shares. Needham & Company LLC reiterated a "buy" rating and set a $11.00 price target on shares of Cryoport in a report on Wednesday, April 16th. Roth Mkm reissued a "buy" rating and issued a $15.00 target price on shares of Cryoport in a report on Tuesday, April 1st. UBS Group upped their price target on Cryoport from $10.00 to $11.00 and gave the company a "buy" rating in a report on Tuesday, April 1st. Finally, Guggenheim reiterated a "buy" rating and issued a $10.00 price objective on shares of Cryoport in a report on Wednesday, April 16th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $11.67.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.